SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (1483)7/2/1997 12:16:00 AM
From: squetch   of 9719
 
PB and all, If you get bored let me know what you think of this:
>>NCI researchers have found that Onconase (a frog RNase), currently in clinical trials as an anti-cancer agent, enhanced vincristine and adriamycin cytotoxicity in cultured parental HT29PAR and in drug resistant HT29MDR1 human colon carcinoma cells as well as in MCF-7Adrr human mammary cancer cells. The in vitro results were confirmed in nude mice given transplants of HT29MDR1 cells followed by treatment with a combination of vincristine and Onconase, thus establishing that Onconase can overcome drug resistance caused by the P-glycoprotein. This was the first study to establish Onconase as a chemosensitizer to VCR. Furthermore, Onconase was found to enhance the effectiveness of MRK-16, an antibody that reverses drug resistance. This observation was particularly interesting since combinations of MRK-16 with conventional chemosensitizers were not more effective than MRK-16 with single agents alone. Since Onconase does not cause myelosuppression, combination therapies are well tolerated in patients. Consequently, Onconase may present a viable new approach to treating the problem of drug resistance.<< nci.nih.gov Company is ACEL and any and all thoughts appreciated. StanQ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News